000304482 001__ 304482
000304482 005__ 20250914022646.0
000304482 0247_ $$2doi$$a10.1038/s41571-025-01069-z
000304482 0247_ $$2pmid$$apmid:40926013
000304482 0247_ $$2ISSN$$a1759-4774
000304482 0247_ $$2ISSN$$a1759-4782
000304482 0247_ $$2altmetric$$aaltmetric:181219027
000304482 037__ $$aDKFZ-2025-01874
000304482 041__ $$aEnglish
000304482 082__ $$a610
000304482 1001_ $$00000-0001-7989-5027$$aPrimac, Irina$$b0
000304482 245__ $$aThe molecular blueprint of targeted radionuclide therapy.
000304482 260__ $$aNew York, NY$$bNature Publ. Group$$c2025
000304482 3367_ $$2DRIVER$$aarticle
000304482 3367_ $$2DataCite$$aOutput Types/Journal article
000304482 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1757570419_26500$$xReview Article
000304482 3367_ $$2BibTeX$$aARTICLE
000304482 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304482 3367_ $$00$$2EndNote$$aJournal Article
000304482 500__ $$aepub
000304482 520__ $$aTargeted radionuclide therapy (TRT) is a cutting-edge treatment approach in oncology that combines the molecular precision of targeted agents with the effect of radiotherapy to selectively deliver cytotoxic radiation to cancer cells. Research efforts from the past few decades have led to a diverse molecular landscape of TRT and have provided lessons for further rational development of targeted radiopharmaceuticals and expansion of the clinical applications of this treatment modality. In this Review, we discuss TRT in the context of therapeutic approaches currently available in oncology, describe the broad range of established and emerging targets for TRT including innovative approaches to exploit vulnerabilities presented by the tumour microenvironment, and address the challenges for clinical translation and molecular optimization. By bridging technological innovation and preclinical discoveries with real-world clinical implementation, ongoing research on TRT is seeking to provide effective and safe treatment options for patients across a variety of cancer types and treatment settings. Overall, we emphasize the transformative potential of TRT and highlight how a comprehensive understanding of what constitutes an optimal target can redefine clinical practice, fostering the evolution of TRT as a highly individualized and adaptable therapeutic option that improves outcomes across a broad range of cancer types.
000304482 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000304482 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304482 7001_ $$00000-0002-8004-3718$$aTabury, Kevin$$b1
000304482 7001_ $$00000-0003-2543-852X$$aTasdogan, Alpaslan$$b2
000304482 7001_ $$aBaatout, Sarah$$b3
000304482 7001_ $$00000-0002-9662-7259$$aHerrmann, Ken$$b4
000304482 773__ $$0PERI:(DE-600)2491414-9$$a10.1038/s41571-025-01069-z$$pnn$$tNature reviews / Clinical oncology$$vnn$$x1759-4774$$y2025
000304482 909CO $$ooai:inrepo02.dkfz.de:304482$$pVDB
000304482 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-2543-852X$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000304482 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-9662-7259$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000304482 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000304482 9141_ $$y2025
000304482 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-12$$wger
000304482 915__ $$0StatID:(DE-HGF)3003$$2StatID$$aDEAL Nature$$d2024-12-12$$wger
000304482 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-12
000304482 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-12
000304482 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-12
000304482 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-12
000304482 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-12
000304482 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-12
000304482 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-12
000304482 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT REV CLIN ONCOL : 2022$$d2024-12-12
000304482 915__ $$0StatID:(DE-HGF)9970$$2StatID$$aIF >= 70$$bNAT REV CLIN ONCOL : 2022$$d2024-12-12
000304482 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000304482 980__ $$ajournal
000304482 980__ $$aVDB
000304482 980__ $$aI:(DE-He78)ED01-20160331
000304482 980__ $$aUNRESTRICTED